← Back to All Filings

Atara Bio CEO Sells $38K in Stock for Tax Withholding

Low SignificanceNovember 19, 2025 at 5:02:19 PM EST

Atara Biotherapeutics, Inc.

$ATRA4CIK: 0001604464

Subscribe to track ATRA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Atara Bio CEO Sells $38K in Stock for Tax Withholding

Company: Atara Biotherapeutics, Inc. (ATRA) Form: 4 | Filed: 2025/11/19 Significance: Low

Insider: Nguyen AnhCo Title: President and CEO | Relationship: Director, Officer

Transaction: • Type: Sell • Shares: 2,915 • Price: ~$13.19 • Value: ~$38,440 • Owned After: 64,974

Key Insight: This was an automatic, non-discretionary sale to cover tax obligations from vesting RSUs, as noted in the filing. It does not reflect a change in the insider's outlook.

Market Context: The sale represents less than 0.04% of the company's $100 million market capitalization.

Comprehensive Analysis

SEC Filing Analysis: Atara Biotherapeutics, Inc. (ATRA)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The President and CEO, Nguyen AnhCo, executed an automatic sale of shares to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).
  • Market Impact: Neutral. This is a non-discretionary transaction with negligible market value.

Company Information

FieldValue
CompanyAtara Biotherapeutics, Inc.
Ticker SymbolATRA
CIK0001604464
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameNguyen AnhCo
CIK0001977970
Title/PositionPresident and CEO
RelationshipDirector, Officer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-17
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved2,915
Price Per Share~$13.19 (Weighted Avg)
Total Value$38,440
Shares Owned After64,974
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$38,440
% of Market Cap0.038%
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The transaction value of approximately $38,440 is insignificant relative to Atara's $100 million market capitalization.
  • Transaction Significance: The sale is classified as having low significance due to its small value and its nature as an automatic 'sell-to-cover' transaction, which is common for executives managing tax liabilities on equity compensation.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The filing explicitly states the sale was automatic to satisfy tax withholding obligations. This is not a discretionary sale reflecting insider sentiment.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
  • Sentiment Indicator: Neutral. The market typically disregards routine, tax-related sales by insiders.

Additional Context

Transaction Notes

  • Special Circumstances: Footnote 1 confirms: "Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement."
Topics:#SECFiling#InsiderTrading#ATRA#AtaraBiotherapeutics#Form4#InsiderSell#StockMarket#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.